Posted by Michael Wonder on 25 Mar 2022
Highlights from the CHMP 21-24 March 2022 meeting
25 March 2022 - The EMA’s CHMP recommended five medicines for approval at its March 2022 meeting.
The monoclonal antibody Evusheld (tixagevimab / cilgavimab) received a positive opinion from the CHMP for the prevention of COVID-19.
